Protalix BioTherapeutics P/E Ratio

Protalix BioTherapeutics's p/e ratio stands at 12.27. That is below the Healthcare sector average of 27.42. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Protalix BioTherapeutics sits lower the Healthcare benchmark (27.42) with a P/E ratio of 12.27. That is roughly 55.3% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 12.27 is attractive depends on Protalix BioTherapeutics's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Protalix BioTherapeutics's P/E ratio evolved across reporting periods, while the comparison chart places PLX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, P/E ratio is commonly used to spot outliers. Protalix BioTherapeutics's reading of 12.27 (sector avg 27.42) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.